Plain-English translation of NCT06560463 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a continuous glucose monitor—a small sensor you wear on your skin for 10 days—can better detect early signs of diabetes in people with cystic fibrosis. Researchers want to compare how well the glucose monitor works compared to the standard blood tests your CF clinic already does. By understanding which method catches diabetes earlier, your care team may be able to help prevent or manage this common complication of cystic fibrosis.
About 40% of people with cystic fibrosis develop diabetes, which can affect their lung health and overall well-being. The standard blood tests used today may not catch early warning signs. Researchers want to know if continuous glucose monitoring can identify these early changes so patients can get help sooner.
You likely qualify if…
You likely don't qualify if…
You would visit your CF clinic and have a small glucose sensor applied to your skin by a clinic dietitian, who will also teach you how to use the companion phone apps to track your readings. Over the next 10 days, you'll wear the sensor (which is the size of a coin) and use your phone to log what you eat and note your carbohydrate intake. You'll also continue with your standard annual blood tests as usual. After 10 days, you'll return to the clinic so your care team can review the glucose monitor data and compare it with your regular blood test results.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States